文献速递神经肿瘤

将第二程放疗前移:复发胶质瘤手术切除后早期再照射可提高疗效且耐受性极佳

Moving Second Courses of Radiotherapy Forward: Early Re-Irradiation After Surgical Resection for Recurrent Gliomas Improves Efficacy With Excellent Tolerability.
PubMed 文献 · Neurosurgery · 2018-01-01

该研究纳入2002至2016年间108例复发胶质瘤患者,均在复发后接受手术切除并联合早期再照射(中位剂量37.5 Gy,范围25 Gy-57 Gy/EQD2),采用高精度技术。再照射后中位随访7个月,手术及再照射后中位生存12个月(范围1-102个月),完全切除对预后有显著影响(P=.03)。作者认为主动切除联合早期再照射可改善生存,早期再照射可能对治疗优化至关重要。

要点

  • 复发胶质瘤手术切除后早期再照射,手术及再照射后中位生存12个月。
  • 完全切除对预后有显著影响(P=.03)。
  • MGMT启动子甲基化、KPS及首次与第二次放疗间隔是最强预后预测因素。

核心结论

  • 复发胶质瘤主动切除联合早期再照射可获得有前景的结局,完全切除和早期再照射可改善生存。
  • 将再照射前移至复发胶质瘤治疗更早时间点(如完全肉眼切除肿瘤后)可能对治疗优化至关重要。
  • 采用先进放疗技术时副作用低。

研究设计与样本

  • 研究纳入2002至2016年间治疗的108例复发胶质瘤患者,所有患者均因复发接受手术切除,并采用高精度技术进行再照射,中位剂量37.5 Gy(范围25 Gy-57 Gy/2 Gy分次等效剂量[EQD2])。
  • 所有患者均在前瞻性跨学科随访项目中随访。

主要发现

  • 再照射后中位随访7个月,手术及再照射后中位生存12个月(范围1-102个月)。
  • 完全切除对结局有显著影响(P=.03)。
  • 结局最强预测因素为MGMT启动子甲基化、卡氏功能状态评分及首次与第二次放疗之间的时间间隔。

临床怎么用

  • 作者认为,复发胶质瘤主动切除联合早期再照射可带来有前景的结局,完全切除和早期再照射可改善生存。
  • 作者提出,将再照射前移至复发胶质瘤治疗更早时间点(如完全肉眼切除肿瘤后)可能对治疗优化至关重要。
  • 作者指出,采用先进放疗技术时副作用低。
  • 目前该理念正在GLIOCAVE/NOA 17试验中评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Generally, re-irradiation (Re-RT) is offered to patients with glioma recurrences with macroscopic lesions. Results are discussed controversially, and some centers postulate limited benefit of Re-RT. Re-RT is generally offered to tumors up to 4 cm in diameter. Re-resection is also discussed controversially; however, recent studies have shown significant benefit. OBJECTIVE: To combine proactive re-resection and early Re-RT in patients with recurrent glioma. METHODS: We included 108 patients treated between 2002 and 2016 for recurrent glioma. All patients underwent surgical resection for recurrence; Re-RT was applied with a median dose of 37.5 Gy (range 25 Gy-57Gy/equivalent dose in 2Gy fractions [EQD2]) with high-precision techniques. All patients were followed prospectively in an interdisciplinary follow-up program. RESULTS: Median follow-up after Re-RT was 7 mo. Median survival after surgery and Re-RT was 12 mo (range 1-102 mo). Complete resection had a significant impact on the outcome (P = .03). The strongest predictors of outcome were MGMT-promotor methylation and Karnofsky Performance Score and time interval between primary and second RT. CONCLUSION: Proactive resection of tumor recurrences combined with early Re-RT conveys into promising outcome in recurrent glioma. Complete resection and early Re-RT lead to improved survival. Thus, moving Re-RT to an earlier timepoint during the treatment of recurrent glioma, eg after complete macroscopic removal of the tumor, may be crucial for treatment optimization. Using advanced RT techniques, side effects are low. Currently, this concept is evaluated in the GLIOCAVE/NOA 17 trial.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Combs SE, Kessel KA, Hesse J, et al. Moving Second Courses of Radiotherapy Forward: Early Re-Irradiation After Surgical Resection for Recurrent Gliomas Improves Efficacy With Excellent Tolerability. Neurosurgery. 2018. PMID: 29462372. doi:10.1093/neuros/nyx629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。